Bridger Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-34,975
| Closed | -$9.44M | – | 26 |
|
|
2025
Q1 | $9.44M | Sell |
34,975
-6,207
| -15% | -$1.6M | 4.69% | 9 |
|
|
2024
Q4 | $9.69M | Buy |
41,182
+4,160
| +11% | +$1.09M | 5.21% | 7 |
|
|
2024
Q3 | $10.2M | Hold |
37,022
| – | – | 5.09% | 5 |
|
|
2024
Q2 | $9M | Sell |
37,022
-15,900
| -30% | -$2.51M | 4.63% | 8 |
|
|
2024
Q1 | $7.91M | Buy |
52,922
+34,000
| +180% | +$5.67M | 3.57% | 10 |
|
|
2023
Q4 | $3.62M | Buy |
+18,922
| New | +$3.22M | 1.39% | 19 |
|
|
2021
Q4 | – | Sell |
-59,804
| Closed | -$11.3M | – | 46 |
|
|
2021
Q3 | $11.3M | Sell |
59,804
-51,500
| -46% | -$9.66M | 1.32% | 27 |
|
|
2021
Q2 | $18.9M | Sell |
111,304
-115,200
| -51% | -$16.9M | 1.76% | 21 |
|
|
2021
Q1 | $32M | Sell |
226,504
-87,128
| -28% | -$13.1M | 2.99% | 16 |
|
|
2020
Q4 | $40.8M | Sell |
313,632
-45,602
| -13% | -$6.09M | 3.11% | 14 |
|
|
2020
Q3 | $52.3M | Hold |
359,234
| – | – | 4.18% | 7 |
|
|
2020
Q2 | $53.2M | Buy |
359,234
+11,661
| +3% | +$1.57M | 4.93% | 6 |
|
|
2020
Q1 | $37.8M | Sell |
347,573
-120,345
| -26% | -$13.9M | 4.38% | 8 |
|
|
2019
Q4 | $53.9M | Buy |
467,918
+116,157
| +33% | +$11.6M | 3.89% | 8 |
|
|
2019
Q3 | $28.3M | Sell |
351,761
-274,955
| -44% | -$21.8M | 2.34% | 23 |
|
|
2019
Q2 | $45.5M | Buy |
626,716
+4,266
| +0.7% | +$327K | 3.57% | 13 |
|
|
2019
Q1 | $58.2M | Sell |
622,450
-36,335
| -6% | -$3.04M | 4.6% | 7 |
|
|
2018
Q4 | $48M | Sell |
658,785
-64,225
| -9% | -$4.94M | 4% | 10 |
|
|
2018
Q3 | $63.3M | Buy |
723,010
+80,544
| +13% | +$8.1M | 3.66% | 12 |
|
|
2018
Q2 | $63.3M | Buy |
642,466
+92,834
| +17% | +$9.21M | 3.43% | 12 |
|
|
2018
Q1 | $65.5M | Buy |
549,632
+49,413
| +10% | +$6.37M | 3.97% | 10 |
|
|
2017
Q4 | $63.6M | Buy |
500,219
+116,286
| +30% | +$14.6M | 4.19% | 8 |
|
|
2017
Q3 | $45.1M | Sell |
383,933
-375,194
| -49% | -$32M | 2.7% | 20 |
|
|
2017
Q2 | $60.5M | Buy |
759,127
+32,036
| +4% | +$2.05M | 3.46% | 8 |
|
|
2017
Q1 | $37.3M | Buy |
727,091
+8,476
| +1% | +$392K | 2.13% | 24 |
|
|
2016
Q4 | $26.9M | Sell |
718,615
-264,425
| -27% | -$11.1M | 1.87% | 25 |
|
|
2016
Q3 | $66.6M | Buy |
983,040
+296,031
| +43% | +$20.9M | 4.49% | 6 |
|
|
2016
Q2 | $38.1M | Sell |
687,009
-110,203
| -14% | -$6.94M | 2.46% | 19 |
|
|
2016
Q1 | $50M | Buy |
797,212
+79,691
| +11% | +$5.3M | 3.46% | 14 |
|
|
2015
Q4 | $67.5M | Buy |
717,521
+5,132
| +0.7% | +$476K | 2.23% | 9 |
|
|
2015
Q3 | $57.2M | Buy |
712,389
+88,509
| +14% | +$9.83M | 3.9% | 9 |
|
|
2015
Q2 | $74.8M | Sell |
623,880
-2,878
| -0.5% | -$344K | 2.37% | 4 |
|
|
2015
Q1 | $65.4M | Buy |
626,758
+62,319
| +11% | +$6.32M | 4.37% | 9 |
|
|
2014
Q4 | $54.8M | Sell |
564,439
-177,249
| -24% | -$16.4M | 3.45% | 8 |
|
|
2014
Q3 | $57.9M | Buy |
741,688
+241,688
| +48% | +$15.6M | 3.95% | 7 |
|
|
2014
Q2 | $31.6M | Buy |
500,000
+60,000
| +14% | +$3.57M | 2.22% | 25 |
|
|
2014
Q1 | $29.5M | Hold |
440,000
| – | – | 1.97% | 28 |
|
|
2013
Q4 | $28.3M | Sell |
440,000
-3,181
| -0.7% | -$190K | 1.98% | 26 |
|
|
2013
Q3 | $28.4M | Sell |
443,181
-583,467
| -57% | -$29.1M | 2.03% | 25 |
|
|
2013
Q2 | $31.8M | Buy |
+1,026,648
| New | +$27.3M | 2.34% | 24 |
|
Other funds holding ALNY
RP
Bridger Management's ALNY Position: Q2 2025 in Review
Bridger Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 34,975 shares — an estimated $9.44M sold.
Bridger Management first reported a position in ALNY in Q2 2013 and held it in 40 quarters. The position peaked at $74.8M in Q2 2015. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.
- Bridger Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Bridger Management sold 34,975 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $9.44M.
- Bridger Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 40 quarters.
- Bridger Management's Alnylam Pharmaceuticals position peaked at $74.8M in Q2 2015.
- 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.
Based on Bridger Management's 13F filing for Q2 2025, filed 11 Aug 2025.